- Dissecting epigenetic aberrations in childhood cancer
- Children’s Cancer Research Institute - CCRI (St. Anna Kinderkrebsforschung)
Master’s thesis: Dissecting epigenetic aberrations in childhood cancer
The Children’s Cancer Research Institute - CCRI (St. Anna Kinderkrebsforschung) is Austria’s leading center for research aimed at advancing the diagnosis and treatment of children’s cancer. It pursues an ambitious basic, translational and clinical research program, including areas such as cancer biology, immunology, and genetics/epigenetics (http://science.ccri.at/). CCRI is part of a flourishing biomedical research hub at the heart of Vienna. It is a renowned research institution with tight links to the St. Anna Children’s Hospital, a leading pediatric cancer center in Europe that is internationally well-connected through European and global networks.
The research group epigenome-based precision medicine lead by Eleni Tomazou (https://science.ccri.at/research/research-areas/solid-tumours/epigenome-based-precision-medicine/) studies the role of epigenetics in pediatric tumors, with the aim to provide tailored therapies for hard-to-treat childhood cancers such as Ewing sarcoma (Ewing sarcoma). By applying state-of-the-art epigenome assays and novel bioin-formatic tools, we have introduced a novel concept in the field of pediatric sarcoma: Ewing sarcoma is an en-hancer disease characterized by widespread epigenetic heterogeneity (Tomazou et al. 2015 Cell Reports; Sheffield et al. 2017 Nature Medicine). Building on this groundbreaking result, we pursue three research directions:
- Understanding the mechanism(s) of Ewing sarcoma initiation, progression, and resistance to therapy
- Establishing novel therapeutic paradigms for pediatric sarcoma
- Developing biomarkers for patient stratification to inform future clinical trials
We have one position for a highly qualified and motivated Master’s student who wants to pursue his/her Master’s thesis in an ambitious research environment pursuing research relevant to childhood cancer. The successful can-didate will receive a monthly allowance of € 446,81 (paid 14 times per year).
The successful candidate will learn and apply state-of-the-art epigenomics, single-cell analysis, CRISPR technology, and chemical screens. Applicants should be enrolled in a Master’s program in the life sciences or a related field (including not only molecular biology and biochemistry, but also computational biology and medicine) and have a strong motivation for pursuing ambitious research. Furthermore, the ideal candidate will have excellent technical skills (wet-lab or computational), a strong academic track record, solid English language skills, enthusiasm and self-motivation, creativity, strong organizational skills, a proactive approach to problem solving, and the desire to work in an international and competitive research environment.
Applications including motivation letter, curriculum vitae, and academic transcripts should be sent by e-mail to Eleni Tomazou, hr(at)ccri.at. Applications will be reviewed on a rolling basis, and all applications received by 15 September 2019 will be considered. Start date is flexible.
- Name: Caroline Schmid